The landscape of hearing healthcare is on the cusp of a profound transformation, moving beyond mere management of hearing loss to active pharmaceutical intervention. This paradigm shift was the central theme of a pivotal expert panel discussion at the Future of Hearing Healthcare (FHH2026) conference, where leading scientists and industry innovators convened to dissect the latest advancements in inner ear therapeutics and their far-reaching implications for millions living with hearing impairment. The discussion provided an illuminating deep dive into one of the fastest-evolving areas in medical science, signaling a future where hearing loss could be treated, and even prevented, with targeted pharmacological solutions.
The Future of Hearing Healthcare (FHH2026): A Confluence of Innovation
The FHH2026 conference serves as a critical forum for charting the trajectory of audiological science and clinical practice. Historically, solutions for sensorineural hearing loss have predominantly relied on assistive technologies such as hearing aids and cochlear implants, which manage symptoms rather than addressing the underlying biological causes. While these devices have dramatically improved quality of life for countless individuals, the absence of disease-modifying drugs has long represented a significant unmet medical need. This year’s panel, titled "Advancing Inner Ear Therapeutics: Research and Real-World Implications," highlighted a burgeoning field where sophisticated biotechnological and pharmacological approaches are now yielding tangible results, challenging the long-held perception of hearing loss as an irreversible condition. The shift towards therapeutic interventions marks a monumental step, offering the promise of restoring lost function and protecting delicate inner ear structures from damage.
The panel was expertly moderated by Brian Taylor, who introduced a distinguished roster of researchers and CEOs from around the globe, each at the forefront of developing groundbreaking inner ear treatments. Their collective work spans a diverse array of mechanisms, from gene therapy to small molecule drugs, and encompasses innovative drug delivery systems designed to overcome the unique anatomical challenges of the inner ear.
Pioneering Companies and Their Breakthroughs
The panel featured four companies, each with distinct approaches to inner ear therapeutics:
Acousia Therapeutics (Germany): Represented by Jonas Dürfjeld Johnsen, Chief Scientific and Chief Development Officer, Acousia Therapeutics, based in Tübingen, Germany, is focused on modulating the Kv7.4 potassium channel, highly expressed in outer hair cells. This channel is crucial for setting the level of amplification and frequency selectivity in the cochlea’s sensory cells. Intriguingly, the same channel is also found in the mitochondria of these cells, suggesting a dual mechanism for modulating activity and protecting against damage. Acousia is currently awaiting the readout of its first Phase 2 clinical trial by the end of Q2, targeting the prevention of cisplatin chemotherapy-induced hearing loss. This condition, often underestimated in adults, affects over 90% of patients receiving cisplatin chemotherapy, highlighting a significant unmet need that Acousia aims to address.
Spiral Therapeutics (USA): Hugo Peris, founder and CEO of Spiral Therapeutics, based in South San Francisco, California, emphasized the company’s decade-long commitment to inner ear disease, with a strong focus on efficient and minimally invasive drug delivery. Their lead therapeutic, SPT-2101, is a long-acting steroid formulation for Meniere’s disease. This same formulation is also being explored for its application in cochlear implantation, supported by a recent collaboration with Advanced Bionics, a leading cochlear implant company. Beyond steroids for inflammation and structural protection, Spiral Therapeutics is developing a pipeline of neuroprotective strategies and treatments for chemotherapy-induced hearing loss, echoing Acousia’s mission. Having recently secured Series B funding, the company aims to advance SPT-2101 towards a Phase 2b/3 study for Meniere’s disease in 2027, with the ambitious goal of drug approval within the next few years.
Sound Pharmaceuticals (USA): Jonathan Kil, co-founder and CEO of Sound Pharmaceuticals, is advancing a small molecule taken orally that targets glutathione peroxidase 1 (GPx1). This enzyme is highly expressed in the three critical structures involved in the majority of hearing loss and tinnitus. Sound Pharmaceuticals boasts Phase 2 success across three different indications and recent Phase 3 success in Meniere’s disease, leading to the coveted Breakthrough Therapy designation from the FDA. The company has ongoing studies in Meniere’s and cochlear implantation, collaborating with MED-EL, another prominent cochlear implant company. Their ultimate vision includes using this drug for age-related hearing loss and chronic tinnitus, with an anticipated approval for Meniere’s disease next year and subsequent label expansion.
Cilcare (France/Japan): Celia Belline, co-founder and CEO of Cilcare, a biotech company with a strong presence in Japan through a collaboration with Shionogi, presented their lead compound, CL001. This is a single transtympanic administration in a gel format, designed to diffuse into the cochlea to address cochlear synaptopathy – the difficulty of hearing in noisy environments, often considered an early stage of age-related hearing loss. Cilcare is entering Phase 2a with two studies: one in the US focusing on tinnitus patients to restore speech-in-noise perception, and another in Europe across 5 countries and 20 centers, targeting Type 2 diabetes patients. Beyond drug development, Cilcare is heavily invested in improving hearing loss detection, building tools and algorithms for precise patient phenotyping and diagnosis.
A Transformative Era: Key Milestones and Evolving Practices
The panel unanimously agreed that the field is experiencing an unprecedented surge of momentum, largely catalyzed by a recent landmark achievement: the regulatory authorization and approval of Regeneron’s gene therapy for OTOF-related auditory neuropathy in the US market. Celia Belline highlighted the remarkable speed of this development, noting that bringing such a drug to approval in less than 10 years is an extraordinary feat in the pharmaceutical industry. While this therapy targets a relatively narrow patient population, its success provides immense validation and a powerful impetus for all other therapeutic modalities, including the small molecules being developed by the panel’s companies.
Jonas Dürfjeld Johnsen added a crucial perspective, emphasizing the unique advantages that contributed to the gene therapy’s rapid success. These included a narrow, homogeneous patient population with clear identification, a large pharmacodynamic window, and a starting point of complete hearing loss, making any improvement readily detectable. He cautioned that most other programs face greater challenges due to patient heterogeneity, varied medical histories, and the complexities of drug repositioning, underscoring the need for extreme conscientiousness in clinical trial design.
Jonathan Kil, reflecting on his 24 years in the field, echoed the sentiment of humility and perseverance, noting the numerous companies that have come and gone. He recounted Decibel Therapeutics’ journey, which evolved from initial goals involving neurotrophins for cochlear synaptopathy and local sodium thiosulfate for ototoxicity, before achieving success with the otoferlin variant. Kil underscored the critical elements for successful drug development: sound biology, the right target and compound, testing in multiple study populations, and meticulously defined clinical protocols with endpoints accepted by regulators as clinically relevant and disease-modifying. While the initial results for OTOFURLAN appear disease-modifying, he stressed the need for 5-year follow-up studies to confirm durability for full approval.
Hugo Peris reinforced the panel’s long-term commitment to pathology and patient solutions, not just pharmaceutical excitement. He noted that market dynamics often influence research directions, with gene therapies garnering significant funding interest. While the Regeneron success is exciting, he pointed out that other major players like Lilly are also making substantial commitments to advanced therapies, including cell therapy efforts by companies like Lineage and Rinri. Peris highlighted the enduring importance of small molecules, representing the "original spirit of pharmaceutical development," which can leverage well-established mechanisms from other fields and translate them into otology.
Beyond specific drug modalities, the panel identified significant improvements in clinical trial design for hearing loss. These include a more precise definition of primary and secondary endpoints, more rigorous inclusion/exclusion criteria for patient populations, and the adoption of central reading of data—a standard practice in other therapeutic areas that was surprisingly absent in audiology until recently. The mechanisms of action being explored are also broadening, encompassing anti-inflammatory, neuroprotective, anti-oxidative, and anti-apoptotic pathways, with some researchers even investigating "cocktail approaches" to address the multi-faceted nature of hearing loss.
Integrating Therapeutics into Clinical Practice: Challenges and Opportunities
The discussion then pivoted to how these nascent inner ear therapeutics might integrate into clinical practice, particularly for hearing care professionals. Jonas Dürfjeld Johnsen emphasized that the integration would be gradual, not an immediate revolution. He highlighted the recent approval of Phenix Bio’s PBM-001 (formerly SP-105) for acute inner ear disorders as a small molecule success story, alongside the gene therapy. He noted that most new drug approvals still involve small molecules (50-60%), suggesting their continued relevance.
Initial treatments, he predicted, would likely target "narrower populations" (e.g., genetic hearing loss, chemotherapy-induced) and remain largely hospital-based. The real "flip" in clinical practice would occur with the availability of "broader-acting orals" that can be prescribed more generally. He also noted that the traditional "wait and see" approach to hearing loss diagnosis has complicated patient recruitment for clinical trials, and that successful therapies for specific subgroups could create a "flywheel effect" of increased awareness, investment, and easier recruitment.
Jonathan Kil elaborated on the challenges of local delivery, which often requires highly specialized surgeons (otologists, neurotologists, pediatric otolaryngologists), numbering only about 1,000 in the US. For truly broad impact on millions of patients, systemic delivery (oral or subcutaneous injection) would be necessary. He acknowledged the complexity of identifying appropriate drug targets across different age groups, as the biology of hearing loss can vary significantly from neonates to older patients.
Hugo Peris offered a compelling counterpoint, drawing a parallel with the field of ophthalmology. He explained how retinal diseases, once primarily surgical, were revolutionized by the advent of local injections (e.g., anti-VEGFs for wet AMD). Despite initial patient reluctance, intravitreal injections became a widely accepted and impactful treatment, leading to better diagnostic precision and the breakdown of "bucket diagnoses" into specific subsets. Peris envisioned a similar evolution for otology, where initial success with local delivery could establish a precedent, incentivize patient flow, and drive clinicians to adopt minimally invasive procedures performed in clinic settings. This, in turn, would foster better diagnosis and lead to a more tailored approach to treating diverse forms of inner ear diseases.
Celia Belline pushed the discussion even further, downplaying the route of administration as a significant barrier. Drawing comparisons to aesthetic surgery, she argued that transtympanic local administration could become widely accessible, potentially even with out-of-pocket payment models. Her primary focus, however, was on the impending revolution in diagnostics and patient detection. She highlighted the potential of major tech players like Apple, with ubiquitous devices like AirPods constantly monitoring hearing, to "screen patients and drive patients to the right doctors for the right treatment." She cited the CDC’s long-standing, yet often unenforced, recommendation for annual hearing tests in Type 2 diabetes patients as an example of a missed opportunity that tech could help rectify.
Belline passionately advocated for reframing hearing loss as a critical "risk factor" for other chronic diseases, particularly brain diseases like dementia. She drew parallels to how hypertension, high cholesterol, and obesity are treated as risk factors for cardiovascular disease. The growing scientific consensus, as highlighted by the Lancet Commission, links a 10-decibel hearing loss (above mild to moderate) to a 10-15% increased risk of developing dementia, a figure that can rise to 50% for more significant hearing loss. This perspective, she argued, would fundamentally transform market access and elevate otology from a "little niche" to a crucial entry point for overall health, engaging a broader spectrum of medical professionals beyond just otologists and ENTs.
Jonas Dürfjeld Johnsen agreed with the "building blocks" approach, where individual successes, regardless of delivery method, create awareness and investment, leading to a "flywheel effect" that eventually addresses the billions of patients globally. Jonathan Kil underscored the challenge of visualizing the cochlea and its cellular components (hair cells, supporting cells, spiral ganglion neurons, stria vascularis), which are critical to 99% of hearing loss and tinnitus. Unlike ophthalmology, where vascular leaking or drusen are visible, the bone-encapsulated, tiny cochlea (1/20th the volume of the eye) remains largely inaccessible to direct cellular imaging. This diagnostic limitation complicates targeted therapy. He noted that while telehealth can aid in screening, true diagnostics still require clinical audiologists. For conditions like tinnitus, which currently lack objective measures and rely on patient reports, an effective drug could have broad utility and be prescribed via telehealth, though the significant placebo effect (up to 60% in Meniere’s, 40% in tinnitus) remains a challenge.
The Near Future: A Horizon of Optimism
As the panel concluded, the focus shifted to the most optimistic prospects for the coming years. Hugo Peris expressed his hope for more therapy approvals and increased funding for companies in the field, believing that successful outcomes will drive further innovation and capture the imagination of clinicians, patients, and investors. He praised Cilcare’s efforts in improving diagnosis and identifying patient subsets, seeing it as crucial for driving future opportunities.
Celia Belline reiterated her optimism, noting the "lot of margin" for drug development in hearing given the relatively small number of drugs that have reached clinical development compared to other therapeutic areas. She emphasized the critical role of the "era of artificial intelligence" in accelerating progress. For AI to be effective, however, it demands "mega data sets" that go beyond simple audiograms, incorporating audiology, electrophysiology, blood biomarkers, and imaging. This comprehensive data, she argued, would allow for the diagnosis of previously unknown hearing diseases, with distinct pathophysiogenesis, and foster collaboration between biotechs, tech players, audiologists, and hearing aid/cochlear implant companies.
Jonathan Kil highlighted the evolution in clinical practice towards a focus on "speech discrimination," especially in noisy environments, as a key driver for patients seeking therapy. He believes that once a therapy with broader applicability emerges, it will define the market and diagnoses more precisely, creating further opportunities for drug development, much like the label expansion seen with VEGF inhibitors in ophthalmology. He also emphasized the collective perseverance of the four companies, each having committed over a decade to this challenging field.
Jonas Dürfjeld Johnsen advocated for the full utilization of existing diagnostic tools, such as performing a complete audiogram up to 16 kHz. He cited the example of cisplatin-induced hearing loss, where extending the audiogram revealed that 90-95% of adults suffer significant hearing loss, far higher than previously thought, validating patient experiences and providing richer data for AI analysis. He expressed strong optimism for the increased attention and impact driven by major players like Regeneron (and potentially Lilly) entering the market. If future approved drugs also prove profitable, it would further accelerate funding and development.
In summary, the FHH2026 panel painted a vibrant picture of a field undergoing rapid evolution. The collective dedication, scientific rigor, and strategic vision of these pioneering companies, coupled with technological advancements in diagnostics and the growing recognition of hearing loss’s systemic health implications, are poised to redefine hearing healthcare. The journey from managing symptoms to treating underlying causes is long and complex, but the momentum is undeniable, promising a future where pharmaceutical solutions offer real hope for millions affected by hearing loss.
For those interested in delving deeper into these groundbreaking efforts, further information can be found at:
- Acousia Therapeutics: acousia.com
- Spiral Therapeutics: spiraltx.com
- Sound Pharmaceuticals: soundpharma.com
- Cilcare: cilcare.com
